Holen Sie sich die Stockscreener-App
112.47
0.79%
0.88
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$111.59
Offen:
$111.6
24-Stunden-Volumen:
7.52M
Relative Volume:
0.65
Marktkapitalisierung:
$194.62B
Einnahmen:
$46.59B
Nettoeinkommen (Verlust:
$5.41B
KGV:
36.35
EPS:
3.0938
Netto-Cashflow:
$7.38B
1W Leistung:
-3.58%
1M Leistung:
+4.85%
6M Leistung:
-3.33%
1J Leistung:
-14.39%
1-Tages-Spanne:
$111.11
$112.75
1-Wochen-Bereich:
$111.11
$117.34
52-Wochen-Spanne:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
112.47 | 197.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.69 | 125.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
91.23 | 118.14B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
46.84 | 71.55B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
90.21 | 51.78B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-22 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Exact Sciences stock enters new chapter after Abbott acquisition - Ad-hoc-news.de
Abbott Agrees to $670 Million Settlement in Premature Infant Formula Litigation - finance.biggo.com
Analyst Raises Abbott Price Target to $135 on Strengthening Cancer Diagnostics Growth and Successful Exact Sciences Integration - TipRanks
TD Cowen raises Abbott Labs stock price target on cancer diagnostics growth - Investing.com
Abbott Laboratories settles multitude of infant formula legal claims - Yahoo Finance
Abbott Bypasses Appeals Process To Settle Ongoing Premature Infant Formula Litigation - Yahoo Finance
Abbott agreed to pay $670 million to settle preterm baby formula lawsuits - qz.com
Abbott Laboratories stock holds firm after Q2 beat - Ad-hoc-news.de
Abbott Laboratories to pay $670 million to settle cases, claims over its formula for premature babies - Times West Virginian
True North Advisors LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Asset Advisors Investment Management LLC Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Exchange Traded Concepts LLC Has $6.85 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stock Position Raised by Financial & Tax Architects LLC - MarketBeat
Capital Investment Advisory Services LLC Sells 12,335 Shares of Abbott Laboratories $ABT - MarketBeat
ABN Amro Investment Solutions Purchases 19,480 Shares of Abbott Laboratories $ABT - MarketBeat
Alecta Tjanstepension Omsesidigt Acquires 153,500 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Inks $670M Deal To End Some Preterm Formula Claims - Law360
Abbott Will Pay $670 Million To End 2,000 Infant Formula Claims - NDTV Profit
Did Abbott’s Q2 Beat and Profit Hike Just Shift Abbott Laboratories’ (ABT) Investment Narrative? - simplywall.st
Abbott to pay $670 million to settle some preterm infant formula cases - The Lufkin Daily News
Abbott Reaches $670 Million Settlement in Infant Formula Litigation - Devdiscourse
Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge? - Yahoo Finance
Abbott Laboratories Reaches $670 Million Settlement in NEC Infant Formula Lawsuits - Kalkine Media
Abbott to Pay $670 Million to Settle Baby-Formula Litigation - WSJ
Abbott agrees to $670 million settlement of infant formula cases - The Lufkin Daily News
Abbott settles preterm formula litigation for $670 million By Investing.com - Investing.com Canada
Abbott's $670 Million Settlement Resolves Infant Formula Legal Claims - Devdiscourse
Abbott in $670M settlement for some NEC infant formula claims (ABT:NYSE) - Seeking Alpha
Abbott agrees to pay ~$670M to resolve Gill case and ~2,000 related preterm formula claims - TradingView
Abbott settles $670M lawsuits over preterm infa... - Pluang
Abbott Will Pay $670 Million to End 2,000 Infant Formula Claims - Bloomberg.com
Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants - PR Newswire
Abbott pays $670 million to settle 2,000 baby formula claims - Crain's Chicago Business
MiniMed Ships MiniMed Flex With Abbott's Smallest Instinct Sensor - Yahoo! Finance Canada
Avricore and Abbott Labs sign UK pharmacy testing deal | 2026-08-20 | Investing News - Stockhouse
Mirae Asset Global Investments Co. Ltd. Raises Position in Abbott Laboratories $ABT - MarketBeat
Murphy Pohlad Asset Management LLC Purchases 12,140 Shares of Abbott Laboratories $ABT - MarketBeat
Citizens National Bank Trust Department Acquires 11,285 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth? - Yahoo Finance
Abbott settles appeal of $495 million infant formula verdict - Investing.com
Richard W. Allen of Georgia’s 12th district makes significant trades in Abbott Laboratories and Advanced Micro Devices - Investing.com India
Abbott Laboratories (ABT) Could Be 5% Undervalued Following MiniMed Pump Launch - simplywall.st
UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability - simplywall.st
Abbott settles appeal over $495 million infant formula verdict - Reuters
Abbott Laboratories posts 4.8% sales growth in Q2 2026, driven by nutrition, diagnostics, and devices. - Pluang
Here's How Abbott's Medical Devices Arm Acts as a Growth Catalyst - The Globe and Mail
Abbott Laboratories: Diagnostics And Medical Devices Fuel Next Growth Phase (Downgrade) - Seeking Alpha
The Smartest Dividend ETF to Buy With $500 Right Now - The Globe and Mail
5 questions on Abbott’s glucose-ketone sensors - MedTech Dive
Abbott Laboratories raises earnings outlook aft... - Pluang
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Abbott Laboratories-Aktie (ABT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
2.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):